Table 4.

Summary of selected published studies on conventionally fractionated radiotherapy for skull base meningiomas.

Authors	Patients (N)	Technique	Median Dose (Gy)/Fractions	Median Volume (mL)	Median Follow-Up (Months)	Local Control	Late Toxicity
Colombo et al., 2009 [108]	150 *	CK	16–25/2–5	7.5 (0.1–64)	30	96	3.5
Fokas et al., 2014 [98]	49 *	LINAC	25–35/5	6.11 (1.9–35.7)	50	92.9 at 5 and 87.5 at 10 years	12 (G2)
Han et al., 2014 [100]	22 *	LINAC	25/5	4.8 (0.88–20.38)	32	95	0.7
Navarria et al., 2015 [109]	26	LINAC	25/5	13°	24.5	93% at 2 years	G3, none
Marchetti et al., 2016 [110]	143	CK	21–25/2–5	8 (0.1–126.3)	44	93 at 5 years	5.1
Marchetti et al., 2019 [111]	168	CK	25/5	7.3 (0.1–76.8)	51	94% at 5 years	3.7

CK, CyberKnife; LINAC, linear accelerator; mean; * including skull base and intracranial meningiomas.